Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

by B2i | Jun 24, 2025 | Press Releases

GAITHERSBURG, Md., June 24, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

by B2i | Jun 20, 2025 | Press Releases

GAITHERSBURG, Md., June 20, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

by B2i | Jun 12, 2025 | Press Releases

GAITHERSBURG, Md., June 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

by B2i | Jun 12, 2025 | Press Releases

GAITHERSBURG, Md., June 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

by B2i | Jun 4, 2025 | Press Releases

GAITHERSBURG, Md., June 04, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...